Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XEP527 in Stable Schizophrenia
NCT07908680Phase 1Not yet recruiting
- Sponsor
- Novartis
- Start
- Nov 2026
- Primary completion
- Mar 2028
01
Overview
Phase 1, randomised, double-blind trial of XEP527 in schizophrenia (6 cohorts), sponsored by Novartis. Primary endpoint: Incidence of adverse events and serious adverse events. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
XEP527
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT07908680.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07908680.